Azra Raza challenges the current approach to cancer research, highlighting the limitations of mouse-driven reductionist methods and the lack of progress in treating acute myeloid leukemia. She calls for a shift in the intellectual infrastructure of the pharmaceutical industry to better understand the complexity of cancer and find more effective treatments.
